Showing 20 of 37 recruiting trials for “galactose-epimerase-deficiency”
RecruitingNCT06906367 ↗
A Study of Patients With Fabry Disease (US Specific)
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RecruitingNCT07235709 ↗
Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
RecruitingNCT06941025 ↗
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease
Enrolling by InvitationNCT06880250 ↗
Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease
👨⚕️ Sergey V. Moiseev, MD, Sechenov First Moscow State Medical University (Sechenov University)📍 23 sites📅 Started Mar 2025View details ↗
RecruitingNCT04252066 ↗
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RecruitingNCT06884358 ↗
Functional Capacity in Anderson-Fabry Disease Patients
RecruitingNCT06663358 ↗
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
👨⚕️ Jianhua Mao, PhD, Children's Hospital, Zhejiang University School of Medicine📍 2 sites📅 Started Oct 2024View details ↗
Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment
👨⚕️ Wladimir MAUHIN, Doctor, Groupe Hospitalier Diaconesses Croix Saint-Simon📍 1 site📅 Started Oct 2024View details ↗
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
👨⚕️ Arian Pano, MD, MPH, Clinical Development and Progam Lead, uniQure Biopharma, B.V.📍 8 sites📅 Started Jun 2024View details ↗
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
👨⚕️ Hong Xu, MD,PhD, Children's Hospital of Fudan University📍 1 site📅 Started Feb 2024View details ↗
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →